J
Jean G. Sathish
Researcher at Pfizer
Publications - 5
Citations - 1074
Jean G. Sathish is an academic researcher from Pfizer. The author has contributed to research in topics: Coronavirus & Protease. The author has an hindex of 4, co-authored 5 publications receiving 120 citations.
Papers
More filters
Posted ContentDOI
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
Dafydd R. Owen,Charlotte Moira Norfor Allerton,Annaliesa S. Anderson,Lisa Aschenbrenner,Melissa Avery,Simon Berritt,Britton Boras,Rhonda D. Cardin,Anthony Carlo,Karen J. Coffman,Alyssa Dantonio,Li Di,Heather Eng,RoseAnn Ferre,Ketan S. Gajiwala,Scott A. Gibson,Samantha Elizabeth Greasley,Brett L. Hurst,Eugene P. Kadar,Amit S. Kalgutkar,Jack C. Lee,Jisun Lee,Wei Liu,Stephen W. Mason,Stephen Noell,Jonathan J. Novak,R. Scott Obach,Kevin Ogilvie,Nandini Chaturbhai Patel,Martin Pettersson,Devendra K. Rai,Matthew R. Reese,Matthew F. Sammons,Jean G. Sathish,Ravi Shankar P. Singh,Claire M. Steppan,Al E. Stewart,Jamison B. Tuttle,Lawrence W. Updyke,Patrick Robert Verhoest,Liuqing Wei,Qingyi Yang,Yuao Zhu +42 more
TL;DR: The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS-CoV-2) has become a global pandemic as discussed by the authors.
Journal ArticleDOI
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
Britton Boras,Rhys M. Jones,Brandon J. Anson,Dan Arenson,Lisa Aschenbrenner,Malina A. Bakowski,Nathan Beutler,Joseph John Binder,Emily I. Chen,Heather Eng,Holly L. Hammond,Jennifer Hammond,Robert Haupt,Robert M. Hoffman,Eugene P. Kadar,Rob Kania,Emi Kimoto,Melanie G. Kirkpatrick,Lorraine F. Lanyon,Emma K. Lendy,Lillis Jonathan Richard,James Logue,Suman Luthra,Chunlong Ma,Stephen W. Mason,Marisa McGrath,Stephen Noell,R. Scott Obach,Matthew N O' Brien,Rebecca E. O’Connor,Kevin Ogilvie,Dafydd R. Owen,Martin Pettersson,Matthew R. Reese,Thomas F. Rogers,Thomas F. Rogers,Romel Rosales,Michelle Rossulek,Jean G. Sathish,Norimitsu Shirai,Claire M. Steppan,Martyn D. Ticehurst,Lawrence W. Updyke,Stuart Weston,Yuao Zhu,Kris M. White,Adolfo García-Sastre,Jun Wang,Arnab K. Chatterjee,Andrew D. Mesecar,Matthew B. Frieman,Annaliesa S. Anderson,Charlotte Moira Norfor Allerton +52 more
TL;DR: In this paper, a phosphate prodrug PF-07304814 was developed to inhibit coronavirus family 3CL protease activity with selectivity over human host protease targets.
Posted ContentDOI
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19
Britton Boras,Rhys M. Jones,Brandon J. Anson,Dan Arenson,Lisa Aschenbrenner,Malina A. Bakowski,Nathan Beutler,Joseph John Binder,Emily I. Chen,Heather Eng,Jennifer Hammond,Robert M. Hoffman,Eugene P. Kadar,Robert Steven Kania,Emi Kimoto,Melanie G. Kirkpatrick,Lorraine F. Lanyon,Emma K. Lendy,Lillis Jonathan Richard,Suman Luthra,Chunlong Ma,Stephen Noell,R. Scott Obach,Kevin Ogilvie,Dafydd R. Owen,Martin Pettersson,Mattew R. Reese,Thomas F. Rogers,Thomas F. Rogers,Michelle Rossulek,Jean G. Sathish,Claire M. Steppan,Martyn D. Ticehurst,Lawrence W. Updyke,Yuao Zhu,Jun Wang,Arnab K. Chatterjee,Andrew D. Mesecar,Annaliesa S. Anderson,Charlotte Moira Norfor Allerton,Matthew B. Frieman,Stuart Weston,Marisa McGrath,James Logue,Robert Haupt,Holly L. Hammond,Stephen W. Mason,Norimitsu Shirai +47 more
TL;DR: The ADME, safety, in vitro, and in vivo antiviral activity data that supports the clinical evaluation of this compound as a potential COVID-19 treatment are presented.
Posted ContentDOI
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Britton Boras,Rhys M. Jones,Brandon J. Anson,Dan Arenson,Lisa Aschenbrenner,Malina A. Bakowski,Nathan Beutler,Joseph John Binder,Emily I. Chen,Heather Eng,Holly L. Hammond,Jennifer Hammond,Rob Haupt,Robert M. Hoffman,Eugene P. Kadar,Robert Steven Kania,Emi Kimoto,Melanie G. Kirkpatrick,Lorraine F. Lanyon,Emma K. Lendy,Lillis,James Logue,Suman Luthra,Chuang Ma,Stephen W. Mason,Marisa McGrath,Stephen Noell,Obach Rs,O’Brien Mn,Rebecca E. O’Connor,Kevin Ogilvie,Dafydd R. Owen,Martin Pettersson,Reese Mr,Thomas F. Rogers,Thomas F. Rogers,Michelle Rossulek,Jean G. Sathish,Norimitsu Shirai,Claire M. Steppan,Martyn D. Ticehurst,Lawrence W. Updyke,Stuart Weston,Yuao Zhu,Jun Wang,Abhishek Chatterjee,Andrew D. Mesecar,Matthew B. Frieman,Annaliesa S. Anderson,Charlotte Moira Norfor Allerton +49 more
TL;DR: In this paper, a phosphate prodrug PF-07304814 is metabolized to PF-00835321 which is a potent inhibitor in vitro of the coronavirus family 3CL pro, with selectivity over human host protease targets.
Posted ContentDOI
An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19
Dafydd R. Owen,Charlotte Moira Norfor Allerton,Annaliesa S. Anderson,Lisa Aschenbrenner,Melissa Avery,Simon Berritt,Britton Boras,Rhonda D. Cardin,Anthony Carlo,Karen J. Coffman,Alyssa Dantonio,Li Di,Heather Eng,RoseAnn Ferre,Ketan S. Gajiwala,Scott A. Gibson,Samantha Elizabeth Greasley,Brett L. Hurst,Eugene P. Kadar,Amit S. Kalgutkar,Jack C. Lee,Jisun Lee,Wei Liu,Stephen W. Mason,Stephen Noell,Jonathan J. Novak,R. Scott Obach,Kevin Ogilvie,Nandini Chaturbhai Patel,Martin Pettersson,Devendra K. Rai,Matthew R. Reese,Matthew F. Sammons,Jean G. Sathish,Ravi Shankar P. Singh,Claire M. Steppan,Al E. Stewart,Jamison B. Tuttle,Lawrence W. Updyke,Patrick Robert Verhoest,Liuqing Wei,Qingyi Yang,Yuao Zhu +42 more
TL;DR: PF-07321332 as mentioned in this paper is an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity, and excellent off-target selectivity and in vivo safety profiles.